Iain Farrance

Biologist at CBER, FDA

Speaker

Iain Farrance is a CMC reviewer in the Office of Cell Therapy and Human Tissue (OCTHT), Office of Therapeutic Products (OTP) in CBER/FDA. Since joining the FDA in 2021, he has served as a CMC reviewer of INTERACT, pre-IND, IND, and BLA submissions for cell therapies and combination products. He has over 20 years broad experience from supply chain and quality control at small cell therapy company to an academic research program focused on gene regulation and signaling in the heart. Dr. Farrance received his Ph.D. from the University of Georgia and did postdoctoral training at UCSF.